Psychedelic Business Spotlight – June 10
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed’s stock is removed from an index; and more!
Psychedelic Spotlight News
-
-
Consolidating Plant Medicine, Permaculture and Indigenous Wisdom With Colette Condorcita, Decriminalize Philadelphia
In this episode, Colette describes her diverse background working closely with plant medicines and Indigenous groups in South America, how psychedelics are intrinsically aligned with permaculture and the cultivation of sacred plants, and much more.
-
Can Psychedelics Improve Scientific Creativity?
Scientific discovery comes from creative insights, and a recently published review details how psychedelics can play a major role in scientific creativity.
-
The History of LSD: A Story of Self-Experimentation
Despite the LSD experience lasting only two hours, Hofmann was amazed at the power of his creation. And like any good scientist, he knew exactly what he had to do: self-experiment.
-
Canada’s Ready for Psychedelic Therapy – CATALYST SUMMIT 2022
The Catalyst Summit 2022 reunited politicians, mycologists, doctors, psychotherapists and…
-
Psychedelic Business Spotlight – June 3
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind files for a new patent; and much more!
-
Does MDMA Reduce Fear? New Study Has Implications for PTSD Treatment
Using a measurement tool called the SCR, researchers found that combining MDMA with fear extinction learning and recall therapy significantly reduced the fear felt by study participants, as compared to the placebo. This may have big implications for how we treat PTSD.
-
British Columbia to Decriminalize Possession of Most Drugs
Those caught with under 2.5 grams of illicit drugs, including heroin and fentanyl, will not face jail time when the regulations go into effect.
-
Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview
In today’s episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA.
ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy.
The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy.
This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend.
In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed.
To learn more about ATMA, visit: https://www.atmajourney.com/
To learn more about Catalyst, visit: https://catalystpresents.ca/#psychedelics #therapy #magicmushrooms
-
5 Next-Generation Psychedelics Entering Clinical Trials This Year
Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation psychedelics on the horizon.
